Recklessness as a hallmark of aggressive cancer

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1659-1665

  Noda, Makoto ^a   Takahashi, Chiaki ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLYCOPROTEIN; MATRIX METALLOPROTEINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN RECK; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER; CANCER INHIBITION; CANCER INVASION; CANCER RESEARCH; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; COLORECTAL CANCER; DISEASE ACTIVITY; DOWN REGULATION; DRUG MECHANISM; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC CODE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL TIME; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 34748812551     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00588.x     Document Type: Review

References (61)

1. Takahashi C, Sheng Z, Horan TP et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95: 13 221-6.
2. Sasahara RM, Takahashi C, Noda M. Involvement of the sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 1999; 264: 668-75.
3. Sasahara RM, Takahashi C, Sogayar MC, Noda M. Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res 1999; 32: 891-5.
4. Sasahara RM, Brochado SM, Takahashi C et al. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev 2002; 26: 435-43.
5. Takenaka K, Ishikawa S, Kawano Y et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 2004; 40: 1617-23.
6. Oh J, Takahashi R, Kondo S et al. The membrane-anchored MMP inhibitor reck is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
7. Oh J, Takahashi R, Adachi E et al. Mutations in two matrix metalloproteinase genes, MMP-2 and mt1-MMP, are synthetic lethal in mice. Oncogene 2004; 23: 5041-8.
8. Rhee JS, Coussens LM. Recking MMP function: Implications for cancer development. Trends Cell Biol 2002; 12: 209-11.
9. Welm B, Mott J, Werb Z. Developmental biology: Vasculogenesis is a wreck without RECK. Curr Biol 2002; 12: R209-11.
10. Weaver VM. Membrane-associated MMP regulators: Novel cell adhesion tumor suppressor proteins? Dev Cell 2002; 2: 6-7.
11. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27.
12. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: A novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003; 22: 167-75.
13. Furumoto K, Arii S, Mori A et al. RECK gene expression in hepatocellular carcinoma: Correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing cysteine-rich protein with kazal motifs. Hepatology 2001; 33: 189-95.
14. Masui T, Doi R, Koshiba T et al. RECK expression in pancreatic cancer: Its correlation with lower invasiveness and better prognosis. Clin Cancer Res 2003; 9: 1779-84.
15. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 2003; 97: 2710-15.
16. Takenaka K, Ishikawa S, Yanagihara K et al. Prognostic significance of reversion-inducing cysteine-rich protein with kazal motifs expression in resected pathologic stage IIIa n2 non-small-cell lung cancer. Ann Surg Oncol 2005; 12: 817-24.
17. Takeuchi T, Hisanaga M, Nagao M et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004; 10: 5572-9.
18. van der Jagt MF, Sweep FC, Waas ET et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (emmprin), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006; 237: 289-97.
19. Ohl F, Jung M, Xu C et al. Gene expression studies in prostate cancer tissue: Which reference gene should be selected for normalization? J Mol Med 2005; 83: 1014-24.
20. Rabien A, Burkhardt M, Jung M et al. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007; 51: 1259-66.
21. Riddick AC, Shukla CJ, Pennington CJ et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005; 92: 2171-80.
22. Li Y, Zhang Y, Zheng Q. Expression of RECK gene and MMP-9 in hilar cholangiocarcinoma and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2005; 25: 552-4.
23. Song SY, Son HJ, Nam E, Rhee JC, Park C. Expression of reversion-inducing-cysteine-rich protein with kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 2006; 42: 101-8.
24. Kumamoto H, Ooya K. Immunohistochemical detection of mt1-MMP, RECK, and emmprin in ameloblastic tumors. J Oral Pathol Med 2006; 35: 345-51.
25. Kang HG, Kim HS, Kim KJ et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res 2007; 25: 696-702.
26. Nabeshima K, Iwasaki H, Nishio J, Koga K, Shishime M, Kikuchi M. Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors. Emmprin and membrane-type (mt) 1-MMP expressions are associated with malignant potential. Anticancer Res 2006; 26: 1359-67.
27. Okamura M, Unami A, Moto M et al. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rash2 mice. Cancer Lett 2007; 245: 321-30.
28. Takagi S, Kato Y, Asano K et al. Matrix metalloproteinase inhibitor RECK expression in canine tumors. J Vet Med Sci 2005; 67: 761-7.
29. Chang HC, Liu LT, Hung WC. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor reck. Cell Signal 2004; 16: 675-9.
30. Hsu MC, Chang HC, Hung WC. Her-2/neu represses the metastasis suppressor RECK via ERK and SP transcription factors to promote cell invasion. J Biol Chem 2006; 281: 4718-25.
31. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998; 95: 3356-61.
32. Kim MS, Son MW, Kim WB, In Park Y, Moon A. Apicidin, an inhibitor of histone deacetylase, prevents h-ras-induced invasive phenotype. Cancer Lett 2000; 157: 23-30.
33. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63: 3069-72.
34. Chang HC, Cho CY, Hung WC. Silencing of the metastasis suppressor RECK by ras oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res 2006; 66: 8413-20.
35. Cho CY, Wang JH, Chang HC, Chang CK, Hung WC. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 2007; 213: 65-9.
36. Chang HC, Cho CY, Hung WC. Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 2007; 98: 169-73.
37. Liu LT, Peng JP, Chang HC, Hung WC. RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 2003; 22: 8263-70.
38. Liu LT, Chang HC, Chiang LC, Hung WC. Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. ONCOGENE 2002; 21: 8347-50.
39. Oh J, Seo DW, Diaz T et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004; 64: 9062-9.
40. Vincent L, Varet J, Pille JY et al. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies. Int J Cancer 2003; 105: 419-29.
41. Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 2006; 25: 4230-4.
42. Chang H, Lee J, Poo H et al. TIMP-2 promotes cell spreading and adhesion via upregulation of Rap1 signaling. Biochem Biophys Res Commun 2006; 345: 1201-6.
43. Correa TC, Brohem CA, Winnischofer SM et al. Downregulation of the reck-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem 2006; 99: 156-67.
44. Takagi S, Hoshino Y, Osaki T, Okumura M, Fuginaga T. Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with kazal motifs in murine cell lines. Exp Oncol 2007; 29: 30-4.
45. Shimizu S, Takagi S, Tamura Y, Osada H. RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines. Cancer Res 2005; 65: 7455-61.
46. Mori T, Moriuchi R, Okazaki E, Yamada K, Katamine S. Tgat oncoprotein functions as an inhibitor of RECK by association of the unique c-terminal region. Biochem Biophys Res Commun 2007; 355: 937-43.
47. Takagi S, Kitamura T, Hosaka Y et al. Molecular cloning of canine membrane-anchored inhibitor of matrix metalloproteinase, RECK. J Vet Med Sci 2005; 67: 385-91.
48. Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-34.
49. Guo J, Zou L. Correlation of RECK with matrix metalloproteinase-2 in regulation of trophoblast invasion of early pregnancy. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 738-40.
50. Srivastava A, Pastor-Pareja JC, Igaki T, Pagliarini R, Xu T. Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion. Proc Natl Acad Sci USA 2007; 104: 2721-6.
51. Echizenya M, Kondo S, Takahashi R et al. The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors. Oncogene 2005; 24: 5850-7.
52. Kondo S, Shukunami C, Morioka Y et al. Dual effects of the membrane-anchored MMP regulator RECK on chondrogenic differentiation of atdc5 cells. J Cell Sci 2007; 120: 849-57.
53. Muraguchi T, Takegami Y, Chandana EPS et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci 2007; 10: 838-45.
54. Miki T, Takegami Y, Okawa K, Muraguchi T, Noda M, Takahashi C. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/ aminopeptidase N and modulates their endocytic pathways. J Biol Chem 2007; 282: 12 341-52.
55. Lei H, Hemminki K, Altieri A et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: Few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007; 103: 61-9.
56. Eisenberg I, Hochner H, Sadeh M, Argov Z, Mitrani-Rosenbaum S. Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene. Cytogenet Genome Res 2002; 97: 58-61.
57. van Lent PL, Span PN, Sloetjes AW et al. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 368-74.
58. Milner JM, Rowan AD, Cawston TE, Young DA. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther 2006; 8: R142.
59. Paulissen G, Rocks N, Quesada-Calvo F et al. Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol Med 2006; 12: 171-9.
60. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
61. 2 in peritoneal macrophage is associated with severity of endometriosis. Am J Pathol 2005; 167: 1061-9.